Cream and radiation combo tackles rare skin cancer

NCT ID NCT05838599

Recruiting now Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining a topical immune-boosting cream (imiquimod) with local radiation can better treat mycosis fungoides, a rare skin lymphoma. About 25 adults with stable but active disease who have tried at least one other therapy will receive the cream for 5 weeks, then two doses of radiation. The study primarily checks safety and skin lesion response at 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: imiquimod cream and radiation therapy
What this could lead to: If it works, this could point toward a more effective combination treatment for mycosis fungoides skin lesions.
What could go wrong: This is a very early, small trial (25 people) testing safety and initial effectiveness. The combination may not work better than radiation alone, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES

Contacts and locations

Locations

Northwestern University Department of Dermatology
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.